JP2003519137A - 抗腫瘍作用を有する置換されたn−ベンジル−インドール−3−イルグリオキシル酸誘導体 - Google Patents

抗腫瘍作用を有する置換されたn−ベンジル−インドール−3−イルグリオキシル酸誘導体

Info

Publication number
JP2003519137A
JP2003519137A JP2001549383A JP2001549383A JP2003519137A JP 2003519137 A JP2003519137 A JP 2003519137A JP 2001549383 A JP2001549383 A JP 2001549383A JP 2001549383 A JP2001549383 A JP 2001549383A JP 2003519137 A JP2003519137 A JP 2003519137A
Authority
JP
Japan
Prior art keywords
group
acid
cooh
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001549383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003519137A5 (cg-RX-API-DMAC7.html
Inventor
ギュンター エックハルト
エーミヒ ペーター
ライヒェルト ディートマー
ルボー ギヨーム
ニッケル ベルント
バッハー ゲラルト
Original Assignee
ツェンタリス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェンタリス アクチエンゲゼルシャフト filed Critical ツェンタリス アクチエンゲゼルシャフト
Publication of JP2003519137A publication Critical patent/JP2003519137A/ja
Publication of JP2003519137A5 publication Critical patent/JP2003519137A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
JP2001549383A 1999-12-23 2000-12-19 抗腫瘍作用を有する置換されたn−ベンジル−インドール−3−イルグリオキシル酸誘導体 Withdrawn JP2003519137A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19962300A DE19962300A1 (de) 1999-12-23 1999-12-23 Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
DE19962300.7 1999-12-23
PCT/EP2000/012947 WO2001047913A2 (de) 1999-12-23 2000-12-19 Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung

Publications (2)

Publication Number Publication Date
JP2003519137A true JP2003519137A (ja) 2003-06-17
JP2003519137A5 JP2003519137A5 (cg-RX-API-DMAC7.html) 2007-10-25

Family

ID=7934006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001549383A Withdrawn JP2003519137A (ja) 1999-12-23 2000-12-19 抗腫瘍作用を有する置換されたn−ベンジル−インドール−3−イルグリオキシル酸誘導体

Country Status (31)

Country Link
US (1) US6432987B2 (cg-RX-API-DMAC7.html)
EP (1) EP1240157B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003519137A (cg-RX-API-DMAC7.html)
KR (1) KR100747425B1 (cg-RX-API-DMAC7.html)
CN (1) CN1283637C (cg-RX-API-DMAC7.html)
AR (1) AR027098A1 (cg-RX-API-DMAC7.html)
AT (1) ATE259364T1 (cg-RX-API-DMAC7.html)
AU (1) AU772745B2 (cg-RX-API-DMAC7.html)
BG (1) BG106924A (cg-RX-API-DMAC7.html)
BR (1) BR0016712A (cg-RX-API-DMAC7.html)
CA (1) CA2395259A1 (cg-RX-API-DMAC7.html)
CO (1) CO5251472A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20022094A3 (cg-RX-API-DMAC7.html)
DE (2) DE19962300A1 (cg-RX-API-DMAC7.html)
DK (1) DK1240157T3 (cg-RX-API-DMAC7.html)
ES (1) ES2215768T3 (cg-RX-API-DMAC7.html)
HK (1) HK1054038B (cg-RX-API-DMAC7.html)
HU (1) HUP0203716A3 (cg-RX-API-DMAC7.html)
IL (1) IL150235A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02006229A (cg-RX-API-DMAC7.html)
NO (1) NO324750B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ533731A (cg-RX-API-DMAC7.html)
PL (1) PL195014B1 (cg-RX-API-DMAC7.html)
PT (1) PT1240157E (cg-RX-API-DMAC7.html)
RU (1) RU2266280C2 (cg-RX-API-DMAC7.html)
SK (1) SK8752002A3 (cg-RX-API-DMAC7.html)
TR (1) TR200400601T4 (cg-RX-API-DMAC7.html)
TW (1) TWI284128B (cg-RX-API-DMAC7.html)
UA (1) UA75060C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001047913A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200204896B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533045A (ja) * 2005-03-11 2008-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Atp結合カセットトランスポーターのモジュレーター

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
JP4878285B2 (ja) * 2003-06-05 2012-02-15 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング アポトーシス誘発作用を有するインドール誘導体
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
MX2007007919A (es) 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
WO2008019357A2 (en) * 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
CA2670778A1 (en) * 2006-11-28 2008-06-05 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (cg-RX-API-DMAC7.html) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
WO1993023374A1 (fr) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Derive d'indole
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
ES2122555T3 (es) * 1994-02-22 1998-12-16 Merrell Pharma Inc Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos.
EP1950200B1 (en) * 1994-04-01 2012-01-11 Eli Lilly And Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
AU6229298A (en) * 1997-02-20 1998-09-09 Shionogi & Co., Ltd. Indole dicarboxylic acid derivatives
US5972988A (en) * 1997-03-26 1999-10-26 Eli Lilly And Company Method for treatment of chronic bronchitis using indole compounds
WO1998047507A1 (en) * 1997-04-24 1998-10-29 Shionogi & Co., Ltd. Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
EP1030661A4 (en) * 1997-10-27 2002-07-17 Lilly Co Eli N, N-DIETHYLGLYCOLAMIDOESTER OF INDOLS AS PRELIMINARY MEDICINE OF SPLA 2 INHIBITORS
WO1999021545A1 (en) * 1997-10-27 1999-05-06 Eli Lilly And Company ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
AU1200899A (en) * 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
WO1999024033A1 (en) * 1997-11-12 1999-05-20 Shionogi & Co., Ltd. Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
EP1039901A1 (en) * 1997-11-14 2000-10-04 Eli Lilly And Company Treatment for alzheimer's disease
GEP20032920B (en) * 1998-02-25 2003-03-25 Genetics Inst Inhibitors of Phospholipase Enzymes
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DZ2770A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
DK1076657T3 (da) * 1998-04-28 2004-11-08 Elbion Ag Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
EA200001140A1 (ru) * 1998-05-01 2001-04-23 Эли Лилли Энд Компани СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ
ID27812A (id) * 1998-05-01 2001-04-26 Lilly Co Eli ESTER PENGHAMBAT sPLA2
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533045A (ja) * 2005-03-11 2008-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Atp結合カセットトランスポーターのモジュレーター

Also Published As

Publication number Publication date
PT1240157E (pt) 2004-06-30
KR20020063245A (ko) 2002-08-01
RU2266280C2 (ru) 2005-12-20
CO5251472A1 (es) 2003-02-28
CA2395259A1 (en) 2001-07-05
NZ519977A (en) 2004-08-27
ZA200204896B (en) 2002-12-20
AR027098A1 (es) 2003-03-12
PL355684A1 (en) 2004-05-17
US6432987B2 (en) 2002-08-13
WO2001047913A2 (de) 2001-07-05
DE50005284D1 (de) 2004-03-18
IL150235A0 (en) 2002-12-01
PL195014B1 (pl) 2007-07-31
CN1420880A (zh) 2003-05-28
HUP0203716A3 (en) 2004-05-28
BG106924A (bg) 2003-04-30
AU772745B2 (en) 2004-05-06
AU2011901A (en) 2001-07-09
US20010014690A1 (en) 2001-08-16
UA75060C2 (en) 2006-03-15
CN1283637C (zh) 2006-11-08
TWI284128B (en) 2007-07-21
HK1054038B (zh) 2007-04-13
DK1240157T3 (da) 2004-06-14
WO2001047913A3 (de) 2002-04-25
EP1240157B1 (de) 2004-02-11
ES2215768T3 (es) 2004-10-16
NO324750B1 (no) 2007-12-03
RU2002120462A (ru) 2004-01-10
NO20023039D0 (no) 2002-06-21
DE19962300A1 (de) 2001-06-28
MXPA02006229A (es) 2003-01-28
SK8752002A3 (en) 2003-01-09
TR200400601T4 (tr) 2004-04-21
NO20023039L (no) 2002-08-09
BR0016712A (pt) 2002-09-03
HK1054038A1 (en) 2003-11-14
NZ533731A (en) 2005-03-24
EP1240157A2 (de) 2002-09-18
ATE259364T1 (de) 2004-02-15
HUP0203716A2 (hu) 2003-03-28
KR100747425B1 (ko) 2007-08-09
CZ20022094A3 (cs) 2002-10-16

Similar Documents

Publication Publication Date Title
JP2002510622A (ja) 抗腫瘍作用を有するインドリル−3−グリオキシル酸誘導体
US6432987B2 (en) Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action
NZ243959A (en) Substituted pyrazine derivatives and pharmaceutical compositions thereof
JP2002505999A (ja) 新規な四環化合物、その製造方法およびこれらの化合物を含有する医薬製剤
JPH0528701B2 (cg-RX-API-DMAC7.html)
JP2000512306A (ja) 5―ht―2c受容体アンタゴニストとして有用なインドリン誘導体
JPH06179651A (ja) 3−アミノエチルインドール類から誘導されるアミジン類およびその製造方法
CN101027283A (zh) 用作血管破坏剂的3,4-二取代马来酰亚胺
CZ20003483A3 (cs) Deriváty indolyl-3-glyoxylové kyseliny s protinádorovým účinkem
MXPA00009646A (en) Indolyl-3-glyoxylic acid derivatives with antitumoral activity
JPWO1994026737A1 (ja) イミダゾリルキノキサリンジオン誘導体及びその医薬組成物
JPH1072439A (ja) ピリジン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070828

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080804